Phagenesis Ltd

Phagenesis is a pioneering MedTech company committed to providing innovative treatments for neurogenic dysphagia, a debilitating swallowing disorder often caused by stroke, brain injury, or prolonged mechanical ventilation. Their flagship product, the Phagenyx Neurostimulation System, utilizes pharyngeal electrical stimulation (PES) to restore neurological control of swallowing by stimulating sensory nerves in the throat. The company boasts a robust portfolio of clinical evidence, including randomized controlled trials and real-world data registries, demonstrating the effectiveness of PES in improving swallowing function, reducing aspiration risk, and ultimately improving patient outcomes.

Phagenesis has achieved significant milestones, including CE marking in Europe and FDA approval in the United States. Their commitment to scientific and clinical excellence is evident in their numerous publications in high-impact journals, showcasing the groundbreaking nature of their work. Phagenesis continues to invest in research and development, with a focus on expanding the use of their technology to treat a wider range of dysphagia patients and ultimately improve patient care and quality of life.

Phagenesis is a pioneering MedTech company dedicated to developing innovative therapies that treat patients suffering from neurogenic dysphagia, a condition characterized by difficulty swallowing. Their mission is to improve the lives of individuals affected by swallowing disorders through the development and application of novel treatments, primarily using pharyngeal electrical stimulation (PES). They aim to restore swallowing control, reduce complications, and accelerate recovery for patients, ultimately enabling them to regain their quality of life and independence.

Phagenesis promotes a culture of scientific and clinical excellence, focused on developing innovative therapies to improve the lives of patients suffering from dysphagia. They are committed to building a dynamic team of talented individuals who are passionate about making a difference. The company is characterized by its commitment to research and development, as evidenced by its numerous clinical publications and ongoing clinical trials. They value collaboration and teamwork, fostering a supportive environment where employees can share ideas and contribute to the company's success.

Phagenesis Ltd. does not explicitly mention a specific approach to diversity, equity, and inclusion on their website. However, they highlight their commitment to "scientific and clinical excellence" and their focus on developing novel therapies to treat patients with neurogenic dysphagia. This suggests a commitment to inclusivity in their patient population, but further information about their approach to diversity, equity, and inclusion within their company is not available.